labetalol has been researched along with Chronic Kidney Failure in 13 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Three renal transplant recipients developed potentially life-threatening hyperkalemia after receiving intravenous labetalol for postoperative hypertension." | 7.68 | Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. ( Arthur, S; Greenberg, A, 1990) |
| " It has also been used intravenously in phaeochromocytoma, tetanus, clonidine withdrawal, and as an adjunct to halothane to produce hypotensive anaesthesia." | 4.76 | Combined alpha- and beta-receptor inhibition in the treatment of hypertension. ( Prichard, BN, 1984) |
| "Three renal transplant recipients developed potentially life-threatening hyperkalemia after receiving intravenous labetalol for postoperative hypertension." | 3.68 | Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. ( Arthur, S; Greenberg, A, 1990) |
| "The efficacy of labetalol in lowering blood pressure was assessed in 18 patients with chronic renal failure and hypertension." | 3.66 | Labetalol in the treatment of hypertensive renal patients. ( Craswell, PW; De Voss, K; Williams, JG, 1978) |
| " Similarly, the absolute bioavailability of an oral dose of 200 mg of labetalol was 0." | 2.67 | Bioavailability of labetalol in patients with end-stage renal disease. ( Awni, WM; Halstenson, CE; Luke, DR; Matzke, GR; Opsahl, JA, 1992) |
| " Values of Cmax, Tmax, half-life or renal elimination did not significantly change with decreased renal function." | 1.28 | The pharmacokinetics of dilevalol in renal impairment. ( Donohue, J; Doyle, GD; Kelly, JG; Laher, MS, 1990) |
| "3 Labetalol has a relatively large apparent volume of distribution (3." | 1.26 | Elimination kinetics of labetalol in severe renal failure. ( Bailey, RR; Ferry, DG; Wood, AJ, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (46.15) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, H | 1 |
| Sim, JJ | 1 |
| Shi, J | 1 |
| Shaw, SF | 1 |
| Lee, MS | 1 |
| Neyer, JR | 1 |
| Kovesdy, CP | 1 |
| Kalantar-Zadeh, K | 1 |
| Jacobsen, SJ | 1 |
| Chhabra, R | 1 |
| Magee, C | 1 |
| Merino, JL | 1 |
| Espejo, B | 1 |
| Ferreiro, P | 1 |
| Bueno, B | 1 |
| Paraíso, V | 1 |
| Kujal, P | 1 |
| Chábová, VČ | 1 |
| Vernerová, Z | 1 |
| Walkowska, A | 1 |
| Kompanowska-Jezierska, E | 1 |
| Sadowski, J | 1 |
| Vaňourková, Z | 1 |
| Husková, Z | 1 |
| Opočenský, M | 1 |
| Skaroupková, P | 1 |
| Schejbalová, S | 1 |
| Kramer, HJ | 1 |
| Rakušan, D | 1 |
| Malý, J | 1 |
| Netuka, I | 1 |
| Vaněčková, I | 1 |
| Kopkan, L | 1 |
| Cervenka, L | 1 |
| Prichard, BN | 1 |
| Lifshits, NL | 1 |
| Ermolenko, VM | 1 |
| Rozhdestvenskaia, TM | 1 |
| Tatsievskiĭ, VA | 1 |
| Panasiuk, VV | 1 |
| El Matri, A | 1 |
| Kechrid, C | 1 |
| Larabi, M | 1 |
| Belkahia, C | 1 |
| Ben Ayed, H | 1 |
| Wood, AJ | 1 |
| Ferry, DG | 1 |
| Bailey, RR | 1 |
| Williams, JG | 1 |
| De Voss, K | 1 |
| Craswell, PW | 1 |
| Luke, DR | 2 |
| Awni, WM | 2 |
| Halstenson, CE | 1 |
| Opsahl, JA | 1 |
| Matzke, GR | 2 |
| Kelly, JG | 1 |
| Laher, MS | 1 |
| Donohue, J | 1 |
| Doyle, GD | 1 |
| Arthur, S | 1 |
| Greenberg, A | 1 |
| Clarkson, JT | 1 |
1 review available for labetalol and Chronic Kidney Failure
| Article | Year |
|---|---|
Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthesia; Antihyp | 1984 |
1 trial available for labetalol and Chronic Kidney Failure
| Article | Year |
|---|---|
Bioavailability of labetalol in patients with end-stage renal disease.
Topics: Administration, Oral; Adult; Biological Availability; Blood Pressure; Female; Humans; Injections, In | 1992 |
11 other studies available for labetalol and Chronic Kidney Failure
| Article | Year |
|---|---|
β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atenolol; Bisoprolol; Carvedilol; Cause of Dea | 2021 |
A case of posterior reversible encephalopathy syndrome.
Topics: Aged; Antihypertensive Agents; Female; Humans; Hypertension; Kidney Failure, Chronic; Labetalol; Pos | 2016 |
[Pregnancy and advanced chronic kidney disease].
Topics: Ductus Arteriosus, Patent; Epilepsy; Female; Fetal Growth Retardation; Humans; Hyaline Membrane Dise | 2010 |
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2010 |
[Labetalol and guanfacine in the treatment of arterial hypertension in patients with chronic renal failure].
Topics: Adolescent; Adult; Antihypertensive Agents; Drug Therapy, Combination; Ethanolamines; Female; Guanfa | 1984 |
[Combined captopril and labetalol treatment of malignant arterial hypertension (author's transl)].
Topics: Adult; Captopril; Drug Synergism; Drug Therapy, Combination; Ethanolamines; Female; Heart Failure; H | 1981 |
Elimination kinetics of labetalol in severe renal failure.
Topics: Adult; Aged; Blood Urea Nitrogen; Creatinine; Ethanolamines; Female; Glomerular Filtration Rate; Hal | 1982 |
Labetalol in the treatment of hypertensive renal patients.
Topics: Adrenergic beta-Antagonists; Adult; Drug Therapy, Combination; Ethanolamines; Female; Humans; Hydral | 1978 |
The pharmacokinetics of dilevalol in renal impairment.
Topics: Administration, Oral; Adult; Aged; Female; Glomerular Filtration Rate; Half-Life; Humans; Hypertensi | 1990 |
Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients.
Topics: Adult; Humans; Hyperkalemia; Hypertension; Infusions, Intravenous; Kidney Failure, Chronic; Kidney T | 1990 |
Improved liquid-chromatographic assay of labetalol in plasma.
Topics: Chromatography, High Pressure Liquid; Humans; Kidney Failure, Chronic; Kinetics; Labetalol; Specimen | 1987 |